Report cover image

Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 191 Pages
SKU # APRC20279264

Description

Summary

According to APO Research, the global Anti-VEGF Drugs for the Treatment of Wet AMD market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Anti-VEGF Drugs for the Treatment of Wet AMD is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Anti-VEGF Drugs for the Treatment of Wet AMD is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Anti-VEGF Drugs for the Treatment of Wet AMD market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Anti-VEGF Drugs for the Treatment of Wet AMD is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Anti-VEGF Drugs for the Treatment of Wet AMD market include Chengdu Kanghong Pharmaceutica, Samsung Bioepis, Roche, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Anti-VEGF Drugs for the Treatment of Wet AMD, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Anti-VEGF Drugs for the Treatment of Wet AMD, also provides the sales of main regions and countries. Of the upcoming market potential for Anti-VEGF Drugs for the Treatment of Wet AMD, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-VEGF Drugs for the Treatment of Wet AMD sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Anti-VEGF Drugs for the Treatment of Wet AMD market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Anti-VEGF Drugs for the Treatment of Wet AMD sales, projected growth trends, production technology, application and end-user industry.

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Company

Chengdu Kanghong Pharmaceutica
Samsung Bioepis
Roche
Regeneron Pharmaceuticals
Novartis
Coherus BioSciences
Biocon Biologics
Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Type

Single target Drugs
Multi-target Drugs
Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Application

Hospital and Clinic
Retail Pharmacies
Other
Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Region

North America

United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Anti-VEGF Drugs for the Treatment of Wet AMD status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Anti-VEGF Drugs for the Treatment of Wet AMD market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Anti-VEGF Drugs for the Treatment of Wet AMD significant trends, drivers, influence factors in global and regions.
6. To analyze Anti-VEGF Drugs for the Treatment of Wet AMD competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Drugs for the Treatment of Wet AMD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Drugs for the Treatment of Wet AMD and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Drugs for the Treatment of Wet AMD.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-VEGF Drugs for the Treatment of Wet AMD market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-VEGF Drugs for the Treatment of Wet AMD industry.
Chapter 3: Detailed analysis of Anti-VEGF Drugs for the Treatment of Wet AMD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Anti-VEGF Drugs for the Treatment of Wet AMD in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Anti-VEGF Drugs for the Treatment of Wet AMD in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2020-2031)
1.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume (2020-2031)
1.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Anti-VEGF Drugs for the Treatment of Wet AMD Market Dynamics
2.1 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Trends
2.2 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Drivers
2.3 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Opportunities and Challenges
2.4 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Restraints
3 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Company
3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Revenue Ranking in 2024
3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Company (2020-2025)
3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Company (2020-2025)
3.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price by Company (2020-2025)
3.5 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Ranking (2023-2025)
3.6 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Manufacturing Base and Headquarters
3.7 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Product Type and Application
3.8 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Anti-VEGF Drugs for the Treatment of Wet AMD Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Type
4.1 Anti-VEGF Drugs for the Treatment of Wet AMD Type Introduction
4.1.1 Single target Drugs
4.1.2 Multi-target Drugs
4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Type
4.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Type (2020-2031)
4.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Type (2020-2031)
4.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Type
4.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Type (2020-2031)
4.3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type (2020-2031)
5 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Application
5.1 Anti-VEGF Drugs for the Treatment of Wet AMD Application Introduction
5.1.1 Hospital and Clinic
5.1.2 Retail Pharmacies
5.1.3 Other
5.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Application
5.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Application (2020-2031)
5.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Application (2020-2031)
5.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Application
5.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Application (2020-2031)
5.3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application (2020-2031)
6 Anti-VEGF Drugs for the Treatment of Wet AMD Regional Sales and Value Analysis
6.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2020-2031)
6.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2020-2025
6.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2026-2031)
6.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Region (2020-2031)
6.4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Region: 2020-2025
6.4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Region (2026-2031)
6.5 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2020-2031)
6.6.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2020-2031)
6.7.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2020-2031)
6.8.2 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2020-2031)
6.9.2 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2020-2031)
6.10.2 Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country, 2024 VS 2031
7 Anti-VEGF Drugs for the Treatment of Wet AMD Country-level Sales and Value Analysis
7.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2020-2031)
7.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2020-2025)
7.3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2026-2031)
7.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country (2020-2031)
7.4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country (2020-2025)
7.4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.5.2 USA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.6.2 Canada Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.8.2 Germany Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.9.2 France Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.9.3 France Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.11.2 Italy Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.12.2 Spain Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.13.2 Russia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.16.2 China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.16.3 China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.17.2 Japan Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.19.2 India Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.19.3 India Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.20.2 Australia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.24.2 Chile Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.26.2 Peru Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.28.2 Israel Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.29.2 UAE Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.31.2 Iran Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Chengdu Kanghong Pharmaceutica
8.1.1 Chengdu Kanghong Pharmaceutica Comapny Information
8.1.2 Chengdu Kanghong Pharmaceutica Business Overview
8.1.3 Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2020-2025)
8.1.4 Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
8.1.5 Chengdu Kanghong Pharmaceutica Recent Developments
8.2 Samsung Bioepis
8.2.1 Samsung Bioepis Comapny Information
8.2.2 Samsung Bioepis Business Overview
8.2.3 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2020-2025)
8.2.4 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
8.2.5 Samsung Bioepis Recent Developments
8.3 Roche
8.3.1 Roche Comapny Information
8.3.2 Roche Business Overview
8.3.3 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2020-2025)
8.3.4 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
8.3.5 Roche Recent Developments
8.4 Regeneron Pharmaceuticals
8.4.1 Regeneron Pharmaceuticals Comapny Information
8.4.2 Regeneron Pharmaceuticals Business Overview
8.4.3 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2020-2025)
8.4.4 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
8.4.5 Regeneron Pharmaceuticals Recent Developments
8.5 Novartis
8.5.1 Novartis Comapny Information
8.5.2 Novartis Business Overview
8.5.3 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2020-2025)
8.5.4 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
8.5.5 Novartis Recent Developments
8.6 Coherus BioSciences
8.6.1 Coherus BioSciences Comapny Information
8.6.2 Coherus BioSciences Business Overview
8.6.3 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2020-2025)
8.6.4 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
8.6.5 Coherus BioSciences Recent Developments
8.7 Biocon Biologics
8.7.1 Biocon Biologics Comapny Information
8.7.2 Biocon Biologics Business Overview
8.7.3 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2020-2025)
8.7.4 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
8.7.5 Biocon Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Anti-VEGF Drugs for the Treatment of Wet AMD Value Chain Analysis
9.1.1 Anti-VEGF Drugs for the Treatment of Wet AMD Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Anti-VEGF Drugs for the Treatment of Wet AMD Sales Mode & Process
9.2 Anti-VEGF Drugs for the Treatment of Wet AMD Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Anti-VEGF Drugs for the Treatment of Wet AMD Distributors
9.2.3 Anti-VEGF Drugs for the Treatment of Wet AMD Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.